Lifevantage (LFVN) Competitors $8.93 +0.26 (+2.94%) As of 02:05 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock LFVN vs. DRUG, LXEO, RAPT, AUTL, CGEM, IVA, PRTC, NGNE, ENGN, and FDMTShould you be buying Lifevantage stock or one of its competitors? The main competitors of Lifevantage include Bright Minds Biosciences (DRUG), Lexeo Therapeutics (LXEO), Rapt Therapeutics (RAPT), Autolus Therapeutics (AUTL), Cullinan Therapeutics (CGEM), Inventiva (IVA), PureTech Health (PRTC), Neurogene (NGNE), enGene (ENGN), and 4D Molecular Therapeutics (FDMT). These companies are all part of the "pharmaceutical products" industry. Lifevantage vs. Its Competitors Bright Minds Biosciences Lexeo Therapeutics Rapt Therapeutics Autolus Therapeutics Cullinan Therapeutics Inventiva PureTech Health Neurogene enGene 4D Molecular Therapeutics Lifevantage (NASDAQ:LFVN) and Bright Minds Biosciences (NASDAQ:DRUG) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends. Which has more risk and volatility, LFVN or DRUG? Lifevantage has a beta of 0.26, indicating that its stock price is 74% less volatile than the S&P 500. Comparatively, Bright Minds Biosciences has a beta of -6.17, indicating that its stock price is 717% less volatile than the S&P 500. Do insiders & institutionals believe in LFVN or DRUG? 35.3% of Lifevantage shares are owned by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are owned by institutional investors. 22.0% of Lifevantage shares are owned by company insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has higher earnings & valuation, LFVN or DRUG? Lifevantage has higher revenue and earnings than Bright Minds Biosciences. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLifevantage$228.53M0.50$9.81M$0.7412.06Bright Minds BiosciencesN/AN/A-$2.06M-$0.93-67.04 Does the media favor LFVN or DRUG? In the previous week, Lifevantage had 1 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 1 mentions for Lifevantage and 0 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 1.29 beat Lifevantage's score of 0.83 indicating that Bright Minds Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Lifevantage Positive Bright Minds Biosciences Positive Is LFVN or DRUG more profitable? Lifevantage has a net margin of 4.29% compared to Bright Minds Biosciences' net margin of 0.00%. Lifevantage's return on equity of 33.75% beat Bright Minds Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Lifevantage4.29% 33.75% 15.26% Bright Minds Biosciences N/A -20.96%-20.66% Do analysts recommend LFVN or DRUG? Lifevantage currently has a consensus target price of $30.50, suggesting a potential upside of 241.74%. Bright Minds Biosciences has a consensus target price of $81.00, suggesting a potential upside of 29.92%. Given Lifevantage's higher probable upside, research analysts plainly believe Lifevantage is more favorable than Bright Minds Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lifevantage 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Bright Minds Biosciences 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.20 SummaryLifevantage beats Bright Minds Biosciences on 10 of the 16 factors compared between the two stocks. Get Lifevantage News Delivered to You Automatically Sign up to receive the latest news and ratings for LFVN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LFVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LFVN vs. The Competition Export to ExcelMetricLifevantageMED/DENTAL IndustryMedical SectorNASDAQ ExchangeMarket Cap$113.26M$18.25B$6.17B$10.68BDividend Yield2.09%1.65%5.72%4.86%P/E Ratio12.0618.4229.6628.53Price / Sales0.502.37580.15129.26Price / Cash7.8513.1737.1261.42Price / Book3.253.1512.086.53Net Income$9.81M$472.95M$3.32B$276.85M7 Day Performance-0.50%5.24%-0.29%0.15%1 Month Performance-15.56%-1.97%5.75%1.68%1 Year Performance-28.71%-6.97%65.71%32.74% Lifevantage Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LFVNLifevantage4.3426 of 5 stars$8.93+2.9%$30.50+241.7%-30.2%$113.26M$228.53M12.06260DRUGBright Minds Biosciences3.098 of 5 stars$64.97+2.7%$81.00+24.7%+31.8%$445.81MN/A-69.86N/APositive NewsLXEOLexeo Therapeutics3.0536 of 5 stars$8.20-0.5%$17.00+107.3%-8.3%$444.97M$650K-2.5258Analyst ForecastAnalyst RevisionRAPTRapt Therapeutics3.7261 of 5 stars$26.35-1.6%$24.78-6.0%+109.5%$443.05M$1.53M-1.8680Trending NewsAnalyst UpgradeAnalyst RevisionAUTLAutolus Therapeutics3.7728 of 5 stars$1.65-0.6%$9.12+452.7%-65.1%$441.80M$10.12M-1.96330Analyst ForecastCGEMCullinan Therapeutics3.6207 of 5 stars$7.83+5.8%$26.00+232.1%-49.1%$437.15MN/A-2.4230Positive NewsInsider TradeGap UpIVAInventiva3.758 of 5 stars$4.61+1.3%$16.14+250.2%+96.0%$435.26M$9.95M0.00100PRTCPureTech Health0.2672 of 5 stars$18.000.0%N/A-18.0%$435.03M$4.83M0.00100News CoverageShort Interest ↑NGNENeurogene1.7982 of 5 stars$31.62+4.7%$46.17+46.0%-38.5%$431.15M$930K-7.3490ENGNenGene2.9935 of 5 stars$8.29-1.2%$19.50+135.2%-10.5%$429.50MN/A-4.3631FDMT4D Molecular Therapeutics3.4673 of 5 stars$9.67+8.7%$30.40+214.4%+27.4%$415.65M$40K-2.74120Analyst ForecastHigh Trading Volume Related Companies and Tools Related Companies Bright Minds Biosciences Competitors Lexeo Therapeutics Competitors Rapt Therapeutics Competitors Autolus Therapeutics Competitors Cullinan Therapeutics Competitors Inventiva Competitors PureTech Health Competitors Neurogene Competitors enGene Competitors 4D Molecular Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LFVN) was last updated on 10/23/2025 by MarketBeat.com Staff From Our PartnersRobinhood warningA strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lifevantage Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Lifevantage With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LFVN Stock Alerts